Krsnaa Diagnostics Limited submitted an investor presentation to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 30 of SEBI LODR Regulations, 2015. The presentation covers financial results for the quarter and year ended March 31, 2026.

Q4 FY26 Financial Performance

  • Revenue: ₹1,926 million (4% YoY growth from ₹1,861 million)
  • EBITDA: ₹559 million (3% YoY growth from ₹545 million)
  • EBITDA Margin: 29% (flat YoY)
  • PAT: ₹417 million (102% YoY growth from ₹207 million)
  • PAT Margin: 22% (1,051 bps improvement from 11%)
  • EPS: ₹12.8 (103% growth from ₹6.3)
  • Patients Served: 4.8 million (1% growth from 4.7 million)
  • PAT includes fair valuation gain of investment in Apulki Healthcare Private Limited amounting to ₹221.75 million

FY26 Annual Financial Performance

  • Revenue: ₹7,728 million (8% YoY growth from ₹7,172 million)
  • EBITDA: ₹2,149 million (10% YoY growth from ₹1,958 million)
  • EBITDA Margin: 28% (69 bps improvement from 27%)
  • PAT: ₹1,013 million (31% YoY growth from ₹776 million)
  • PAT Margin: 13% (231 bps improvement from 11%)
  • EPS: ₹30.9 (31% growth from ₹23.6)
  • Patients Served: 19.8 million (3% growth from 19.2 million)

Operational Metrics

  • 190 CT/MRI Centres
  • 4,700+ Patient Collection Centres
  • 147 Pathology Labs
  • Presence in 18 States/UT across India
  • 59+ Million tests conducted in FY25-26
  • Presence in 331 districts PAN India
  • 350+ radiologists, 100+ pathologists, and 3,000+ qualified professionals
  • 68+ Million patients served in last 5 years
  • 51 centers and 1,167 collection centers operationalized in FY25-26
  • 54 NABL accredited pathology labs (6% growth from 51)
  • 54 NABH accredited radiology centers (74% growth from 32)

Business Model Highlights

  • One of India's largest integrated diagnostic service providers
  • Focus on Public Private Partnership (PPP) model
  • One of India's largest NABH accredited tele-radiology reporting hubs
  • Offers services at over 70% below market rates
  • Pricing strategy: CT Brain at ₹880 (75% below competitors), MRI Brain at ₹1,340 (81% below), CBC at ₹37 (82% below)

Growth Drivers

  • Policy tailwinds with healthcare GDP expected to grow from 3.3% to 5% by 2030
  • Indian healthcare industry estimated at ₹1,017 billion, expected to reach $1,522 billion by FY29-30
  • MoHFW Budget of ₹42 billion for PM-ABHIM in FY 2025-26
  • Retail expansion through asset-light franchise model
  • Hub-and-spoke architecture with centralized reference labs
  • Home collection scale-up with digital platform
  • 24/7 accessibility positioning
  • 30,000+ doctor network across 5 states
  • AI-powered radiology and digital pathology capabilities
  • First company in India to receive American College of Radiology accreditation

ESG Initiatives

  • Workflow digitization eliminated monthly need for 10,000+ papers
  • Effluent treatment plants for wastewater reduction
  • ~23,000+ lives touched through CSR Initiatives

Financial Position (Consolidated)

  • Total Equity: ₹9,803.88 million (up from ₹8,827.70 million)
  • Total Liabilities: ₹8,433.28 million (up from ₹3,988.25 million)
  • Total Equity and Liabilities: ₹18,237.16 million (up from ₹12,815.95 million)
  • Non-current liabilities include borrowings of ₹4,371.44 million and lease liabilities of ₹311.49 million
  • Current liabilities include borrowings of ₹533.61 million and trade payables of ₹632.02 million

Expense Breakdown (Q4 FY26)

  • Cost of Material Consumed: ₹444 million (23% of revenue)
  • Employee Benefits Expense: ₹327 million (17% of revenue)
  • Fees to Hospitals and Others: ₹143 million (7% of revenue)
  • Other Expenses: ₹453 million (24% of revenue)
  • Finance Costs: ₹121 million (6% of revenue)
  • Depreciation: ₹226 million (12% of revenue)
  • Other Income: ₹314 million (16% of revenue)